Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales
Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure
Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production
Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The company’s EBITDA margin remained resilient above 20%
Subscribe To Our Newsletter & Stay Updated